Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), which may not compare with the analyst estimate of ($0.76). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• ArcelorMittal Q2 2026 analyst consensus: $2.04B EBITDA expected
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays